Report Detail
Global (United States, European Union and China) Anti-Diabetic Drugs Market Research Report 2019-2025
- RnM3689545 |
- 22 August, 2019 |
- Global |
- 119 Pages |
- QYResearch |
- Pharma & Healthcare
The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally.
Some of the major drivers and opportunities for growth of this market include drug combinations of several agents such as sitagliptin and metformin and other drug combinations that are in different stages of clinical and pipeline development. Increase in the prevalence of diabetes and new product launches by major pharmaceutical companies re some of the key drivers for growth in this market. In 2015, Boehringer Ingelheim GmbH launched two new drugs (Synjardy & Glyxambi)for treatment of diabetes mellitus type II.
Some of the key opportunities for the antidiabetics include a strong pipeline for antidiabetics and entry of new players in the market, for instance, Novo Nordisk's diabetes drug’s Tresiba, and Ryzodeg received FDA approval in September 2015. Moreover, Boehringer Ingelheim GmbH has a strong pipeline for anti-diabetic drugs, such as Linagliptin which is a dipeptidyl peptidase (DPP) 4 inhibitor) for patients suffering from diabetes mellitus type II and high cardiovascular risk.
In 2019, the market size of Anti-Diabetic Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Anti-Diabetic Drugs.
This report studies the global market size of Anti-Diabetic Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Anti-Diabetic Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Astra Zeneca
Boehringer Ingelheim
Eli Lilly
Johnson & Johnson
Merck
Novartis
Novo Nordisk
Sanofi
Teva Pharmaceutical Industries
Market Segment by Product Type
Biguanides
Sulfonylureas
Meglitinides
Thiazolidinediones
Dipeptidyl Peptidase IV Inhibitors
α-Glucosidase Inhibitors
Market Segment by Application
Type I Diabetes
Type II Diabetes
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Anti-Diabetic Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Anti-Diabetic Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Anti-Diabetic Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Anti-Diabetic Drugs Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Biguanides
- 1.3.3 Sulfonylureas
- 1.3.4 Meglitinides
- 1.3.5 Thiazolidinediones
- 1.3.6 Dipeptidyl Peptidase IV Inhibitors
- 1.3.7 α-Glucosidase Inhibitors
- 1.4 Market Segment by Application
- 1.4.1 Global Anti-Diabetic Drugs Market Share by Application (2019-2025)
- 1.4.2 Type I Diabetes
- 1.4.3 Type II Diabetes
- 1.4.4 Others
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Anti-Diabetic Drugs Market Size
- 2.1.1 Global Anti-Diabetic Drugs Revenue 2014-2025
- 2.1.2 Global Anti-Diabetic Drugs Sales 2014-2025
- 2.2 Anti-Diabetic Drugs Growth Rate by Regions
- 2.2.1 Global Anti-Diabetic Drugs Sales by Regions 2014-2019
- 2.2.2 Global Anti-Diabetic Drugs Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Anti-Diabetic Drugs Sales by Manufacturers
- 3.1.1 Anti-Diabetic Drugs Sales by Manufacturers 2014-2019
- 3.1.2 Anti-Diabetic Drugs Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Anti-Diabetic Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Anti-Diabetic Drugs Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Anti-Diabetic Drugs Market Concentration Ratio (CR5 and HHI)
- 3.3 Anti-Diabetic Drugs Price by Manufacturers
- 3.4 Key Manufacturers Anti-Diabetic Drugs Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Anti-Diabetic Drugs Market
- 3.6 Key Manufacturers Anti-Diabetic Drugs Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Biguanides Sales and Revenue (2014-2019)
- 4.1.2 Sulfonylureas Sales and Revenue (2014-2019)
- 4.1.3 Meglitinides Sales and Revenue (2014-2019)
- 4.1.4 Thiazolidinediones Sales and Revenue (2014-2019)
- 4.1.5 Dipeptidyl Peptidase IV Inhibitors Sales and Revenue (2014-2019)
- 4.1.6 α-Glucosidase Inhibitors Sales and Revenue (2014-2019)
- 4.2 Global Anti-Diabetic Drugs Sales Market Share by Type
- 4.3 Global Anti-Diabetic Drugs Revenue Market Share by Type
- 4.4 Anti-Diabetic Drugs Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Anti-Diabetic Drugs Sales by Application
6 United States
- 6.1 United States Anti-Diabetic Drugs Breakdown Data by Company
- 6.2 United States Anti-Diabetic Drugs Breakdown Data by Type
- 6.3 United States Anti-Diabetic Drugs Breakdown Data by Application
7 European Union
- 7.1 European Union Anti-Diabetic Drugs Breakdown Data by Company
- 7.2 European Union Anti-Diabetic Drugs Breakdown Data by Type
- 7.3 European Union Anti-Diabetic Drugs Breakdown Data by Application
8 China
- 8.1 China Anti-Diabetic Drugs Breakdown Data by Company
- 8.2 China Anti-Diabetic Drugs Breakdown Data by Type
- 8.3 China Anti-Diabetic Drugs Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Anti-Diabetic Drugs Breakdown Data by Company
- 9.2 Rest of World Anti-Diabetic Drugs Breakdown Data by Type
- 9.3 Rest of World Anti-Diabetic Drugs Breakdown Data by Application
- 9.4 Rest of World Anti-Diabetic Drugs Breakdown Data by Countries
- 9.4.1 Rest of World Anti-Diabetic Drugs Sales by Countries
- 9.4.2 Rest of World Anti-Diabetic Drugs Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Astra Zeneca
- 10.1.1 Astra Zeneca Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Anti-Diabetic Drugs
- 10.1.4 Anti-Diabetic Drugs Product Introduction
- 10.1.5 Astra Zeneca Recent Development
- 10.2 Boehringer Ingelheim
- 10.2.1 Boehringer Ingelheim Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Anti-Diabetic Drugs
- 10.2.4 Anti-Diabetic Drugs Product Introduction
- 10.2.5 Boehringer Ingelheim Recent Development
- 10.3 Eli Lilly
- 10.3.1 Eli Lilly Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Anti-Diabetic Drugs
- 10.3.4 Anti-Diabetic Drugs Product Introduction
- 10.3.5 Eli Lilly Recent Development
- 10.4 Johnson & Johnson
- 10.4.1 Johnson & Johnson Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Anti-Diabetic Drugs
- 10.4.4 Anti-Diabetic Drugs Product Introduction
- 10.4.5 Johnson & Johnson Recent Development
- 10.5 Merck
- 10.5.1 Merck Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Anti-Diabetic Drugs
- 10.5.4 Anti-Diabetic Drugs Product Introduction
- 10.5.5 Merck Recent Development
- 10.6 Novartis
- 10.6.1 Novartis Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Anti-Diabetic Drugs
- 10.6.4 Anti-Diabetic Drugs Product Introduction
- 10.6.5 Novartis Recent Development
- 10.7 Novo Nordisk
- 10.7.1 Novo Nordisk Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Anti-Diabetic Drugs
- 10.7.4 Anti-Diabetic Drugs Product Introduction
- 10.7.5 Novo Nordisk Recent Development
- 10.8 Sanofi
- 10.8.1 Sanofi Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Anti-Diabetic Drugs
- 10.8.4 Anti-Diabetic Drugs Product Introduction
- 10.8.5 Sanofi Recent Development
- 10.9 Teva Pharmaceutical Industries
- 10.9.1 Teva Pharmaceutical Industries Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Anti-Diabetic Drugs
- 10.9.4 Anti-Diabetic Drugs Product Introduction
- 10.9.5 Teva Pharmaceutical Industries Recent Development
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Anti-Diabetic Drugs Sales Channels
- 11.2.2 Anti-Diabetic Drugs Distributors
- 11.3 Anti-Diabetic Drugs Customers
12 Market Forecast
- 12.1 Global Anti-Diabetic Drugs Sales and Revenue Forecast 2019-2025
- 12.2 Global Anti-Diabetic Drugs Sales Forecast by Type
- 12.3 Global Anti-Diabetic Drugs Sales Forecast by Application
- 12.4 Anti-Diabetic Drugs Forecast by Regions
- 12.4.1 Global Anti-Diabetic Drugs Sales Forecast by Regions 2019-2025
- 12.4.2 Global Anti-Diabetic Drugs Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Anti-Diabetic Drugs. Industry analysis & Market Report on Anti-Diabetic Drugs is a syndicated market report, published as Global (United States, European Union and China) Anti-Diabetic Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Anti-Diabetic Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
